Vertex Pharmaceuticals Incorporated VRTX announced that the FDA has approved its oral, non-opioid, highly selective NaV1.8 pain signal inhibitor, suzetrigine, for the treatment of adults with moderate-to-severe acute pain. The pain drug will be marketed by the name of Journavx.
Following the nod, Journavx has become the first and only non-opioid oral pain signal inhibitor and the first new class of pain medicine to be approved by the FDA in more than 20 years.
Per the company, Journavx has the potential to transform the treatment paradigm of acute pain. Pain is an area with limited treatment options, mostly highly addictive opioid-based medications.
Vertex believes Journavx, a non-opioid drug, is an effective and well-tolerated medicine for use in all types of moderate-to-severe acute pain.
Shares of VRTX were up more than 8% in after-hours trading on Jan. 30 following the news announcement. The stock was also up in pre-market trading on Jan. 31.
The stock has risen 1.2% in the past year against the industry’s decline of 10.2%.
Image Source: Zacks Investment Research
The FDA accepted the new drug application (“NDA”) for Journavx in July 2024.
VRTX Developing Suzetrigine for Other Indications
Besides acute pain, suzetrigine is also being developed for the treatment of diabetic peripheral neuropathy and painful lumbosacral radiculopathy (“LSR”).
The company’s stock nosedived in December 2024, when it announced data from a phase II study on suzetrigine, for treating painful LSR, a form of peripheral neuropathic pain.
Data from the study showed that treatment with suzetrigine led to a statistically significant and clinically meaningful within-group reduction in pain from baseline with a mean change in numeric pain rating scale of -2.02 at week 12, thereby meeting the primary endpoint. The placebo arm demonstrated a reduction of -1.98 points, indicating not much difference between the two groups.
Overall, investors were not impressed with the data as it showed largely undifferentiated pain reduction on treatment with suzetrigine compared to the placebo arm.
Despite the unimpressive data in the phase II study, management decided to proceed with the phase III study in this indication, which was considered a risky decision.
Vertex initiated a pivotal phase III program of suzetrigine in diabetic peripheral neuropathy, a form of peripheral neuropathic pain caused by damage to nerves, in the third quarter of 2024.
It remains to be seen how Journavx performs in the acute pain indication, especially after disappointing data from the LSR study.
VRTX's Zacks Rank & Stocks to Consider
Vertex currently carries a Zacks Rank #3 (Hold).
Some better-ranked stocks in the biotech sector are Castle Biosciences, Inc. CSTL, Harmony Biosciences Holdings, Inc. HRMY and BioMarin Pharmaceutical Inc. BMRN, each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Castle Biosciences’ loss per share have narrowed from $1.88 to $1.70 for 2025. In the past year, shares of CSTL have increased 21.2%.
CSTL’s earnings beat estimates in each of the trailing four quarters, the average surprise being 172.72%.
In the past 60 days, estimates for Harmony Biosciences’ earnings per share have increased from $2.64 to $3.22 for 2025. In the past year, shares of HRMY have rallied 25.3%.
HRMY’s earnings beat estimates in three of the trailing four quarters while missing the same on the remaining occasion, the average surprise being 147.24%.
In the past 60 days, estimates for BioMarin’s earnings per share have moved up from $3.94 to $4.02 for 2025. In the past year, shares of BMRN have plunged 27.6%.
BMRN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 28.70%.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpBioMarin Pharmaceutical Inc. (BMRN) : Free Stock Analysis Report
Vertex Pharmaceuticals Incorporated (VRTX) : Free Stock Analysis Report
Castle Biosciences, Inc. (CSTL) : Free Stock Analysis Report
Harmony Biosciences Holdings, Inc. (HRMY) : Free Stock Analysis Report
To read this article on Zacks.com click here.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
